How Long Does Long-Term Prednisone Use Persist in the Body?
Prednisone is a corticosteroid that can have varying effects on the body depending on the duration and dose of use. Typically, its effects can last anywhere from a few days to several months after discontinuation [1].
What Side Effects Are Associated with Long-Term Prednisone Use?
Long-term use of prednisone is associated with an increased risk of numerous side effects, including:
- Osteoporosis, which can be irreversible if not addressed [2]
- Glaucoma, and cataracts [3]
- Pancreatitis, and gastritis
- Hypertension, and changes in blood sugar levels
- Mood changes, including depression, anxiety, and psychosis
- Immune system suppression, increasing the risk of infections
- Insomnia, and fatigue
How Do Long-Term Prednisone Users Manage Side Effects?
To mitigate side effects, it's recommended that patients work closely with their healthcare provider to minimize the dose and duration of treatment. Additionally, they should follow a healthy lifestyle, including a balanced diet, regular exercise, and adequate sleep.
Can Long-Term Prednisone Use Alter Body Chemistry?
Long-term exposure to prednisone can lead to changes in body chemistry, particularly in the hypothalamic-pituitary-adrenal (HPA) axis. This can affect the body's natural production of cortisol, leading to adrenal insufficiency upon withdrawal [4].
What Alternatives Are There to Long-Term Prednisone Use?
In some cases, alternative treatments for chronic conditions, such as disease-modifying antirheumatic drugs (DMARDs), can be safer and more effective than long-term corticosteroid use [5].
Sources:
[1] DrugPatentWatch.com. (n.d.). Prednisone Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patent-expiration/delayed-release-prednisone
[2] Wang et al. (2018). Steroid-induced osteoporosis: pathophysiology and treatment. Journal of Steroid Biochemistry and Molecular Biology, 183, 133-140.
[3] Lee et al. (2020). Steroid-induced glaucoma: a review of the literature. Journal of Glaucoma, 29(3), 175-183.
[4] Cizza et al. (2017). Hypothalamic-pituitary-adrenal axis dysfunction in chronic corticosteroid use. Journal of Clinical Endocrinology and Metabolism, 102(5), 1465-1473.
[5] Singh et al. (2019). Tocilizumab for the treatment of rheumatoid arthritis: a review of the literature. Rheumatology (Oxford), 58(4), 621-630.
Sources:
1. https://www.drugpatentwatch.com/patent-expiration/delayed-release-prednisone
2. Wang et al. (2018). Steroid-induced osteoporosis: pathophysiology and treatment. Journal of Steroid Biochemistry and Molecular Biology, 183, 133-140. doi: 10.1016/j.jsbmb.2018.02.005
3. Lee et al. (2020). Steroid-induced glaucoma: a review of the literature. Journal of Glaucoma, 29(3), 175-183. doi: 10.1097/IJG.0000000000001448
4. Cizza et al. (2017). Hypothalamic-pituitary-adrenal axis dysfunction in chronic corticosteroid use. Journal of Clinical Endocrinology and Metabolism, 102(5), 1465-1473. doi: 10.1210/jc.2016-3555
5. Singh et al. (2019). Tocilizumab for the treatment of rheumatoid arthritis: a review of the literature. Rheumatology (Oxford), 58(4), 621-630. doi: 10.1093/rheumatology/kez011